| Original language | English (US) |
|---|---|
| Pages (from-to) | 334-338 |
| Number of pages | 5 |
| Journal | Cancer |
| Volume | 127 |
| Issue number | 3 |
| DOIs |
|
| State | Published - Feb 1 2021 |
Keywords
- COVID
- cancer prevention
- lung screen
- telehealth
- virtual
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Cancer, Vol. 127, No. 3, 01.02.2021, p. 334-338.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Impact of the COVID-19 pandemic on telehealth research in cancer prevention and care
T2 - A call to sustain telehealth advances
AU - the Smoking Cessation at Lung Examination (SCALE) Research Group
AU - Park, Elyse R.
AU - Chiles, Caroline
AU - Cinciripini, Paul M.
AU - Foley, Kristie L.
AU - Fucito, Lisa M.
AU - Haas, Jennifer S.
AU - Joseph, Anne M.
AU - Ostroff, Jamie S.
AU - Rigotti, Nancy A.
AU - Shelley, Donna R.
AU - Taylor, Kathryn L.
AU - Zeliadt, Steven B.
AU - Toll, Benjamin A.
N1 - Funding Information: Elyse R. Park has received grants from the National Cancer Institute for work performed as part of the current study and has received royalties for chapters on smoking cessation from UpToDate. Caroline Chiles has received a grant from the National Institutes of Health for work performed as part of the current study and serves on a Multidisciplinary Expert Advisory Panel for AstraZeneca for work performed outside of the current study. Paul M. Cinciripini has received a grant from Pfizer for work performed outside of the current study. Jennifer S. Haas has received a grant from the National Cancer Institute for work performed as part of the current study. Jamie S. Ostroff has received royalties from UpToDate for work performed outside of the current study. Nancy A. Rigotti has received a grant from the National Cancer Institute for work performed as part of the current study and has received royalties for chapters on smoking cessation from UpToDate for work performed outside of the current study and previously consulted for Achieve Life Sciences, the manufacturer of an investigational smoking cessation medication. Benjamin A. Toll has received grants from the National Cancer Institute, participated in an advisory group regarding e‐cigarettes for Pfizer, and has testified on behalf of plaintiffs who have filed litigation against tobacco companies as part of work performed outside of the current study. The other authors made no disclosures. Funding Information: Supported by the following grants: R01CA207078, R01CA207158, R01CA196873, R01CA207442, R01CA166147, R01CA207228, R01CA207229, and VA HSR&D IIR‐16‐071.
PY - 2021/2/1
Y1 - 2021/2/1
KW - COVID
KW - cancer prevention
KW - lung screen
KW - telehealth
KW - virtual
UR - http://www.scopus.com/inward/record.url?scp=85092416447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092416447&partnerID=8YFLogxK
U2 - 10.1002/cncr.33227
DO - 10.1002/cncr.33227
M3 - Comment/debate
C2 - 33048350
AN - SCOPUS:85092416447
SN - 0008-543X
VL - 127
SP - 334
EP - 338
JO - Cancer
JF - Cancer
IS - 3
ER -